News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
103,475 Results
Type
Article (6425)
Company Profile (11)
Press Release (97039)
Section
Business (41488)
Career Advice (381)
Deals (7374)
Drug Delivery (49)
Drug Development (9941)
Employer Resources (33)
FDA (1771)
Job Trends (1953)
News (60082)
Policy (4383)
Tag
Academia (277)
Alliances (5994)
Alzheimer's disease (151)
Approvals (1756)
Artificial intelligence (24)
Bankruptcy (67)
Best Places to Work (1535)
Breast cancer (19)
Cancer (135)
Cardiovascular disease (23)
Career advice (326)
Cell therapy (38)
Clinical research (7729)
Collaboration (61)
COVID-19 (343)
C-suite (34)
Data (120)
Diabetes (77)
Diagnostics (848)
Drug pricing (45)
Earnings (17111)
Employer resources (31)
Events (11364)
Executive appointments (119)
FDA (1840)
Funding (68)
Gene therapy (30)
GLP-1 (400)
Government (641)
Healthcare (3211)
Infectious disease (354)
Inflammatory bowel disease (25)
Interviews (43)
IPO (3134)
Job creations (435)
Job search strategy (295)
Layoffs (66)
Legal (1105)
Lung cancer (22)
Manufacturing (45)
Medical device (2375)
Medtech (2376)
Mergers & acquisitions (4265)
Metabolic disorders (241)
Neuroscience (196)
NextGen Class of 2024 (1017)
Non-profit (452)
Northern California (244)
Obesity (161)
Opinion (53)
Patents (22)
People (16608)
Phase I (2424)
Phase II (3552)
Phase III (2754)
Pipeline (63)
Podcasts (25)
Policy (28)
Postmarket research (210)
Preclinical (886)
Press Release (19)
Radiopharmaceuticals (63)
Rare diseases (34)
Real estate (610)
Regulatory (2858)
Research institute (316)
Resumes & cover letters (51)
Southern California (167)
Startups (612)
The Weekly (23)
United States (1974)
Vaccines (75)
Weight loss (167)
Date
Today (38)
Last 7 days (155)
Last 30 days (549)
Last 365 days (6845)
2024 (5899)
2023 (7096)
2022 (9815)
2021 (9963)
2020 (8991)
2019 (7041)
2018 (5538)
2017 (5368)
2016 (4939)
2015 (5627)
2014 (4220)
2013 (3231)
2012 (3486)
2011 (3655)
2010 (3274)
Location
Africa (122)
Arizona (22)
Asia (6905)
Australia (1112)
California (466)
Canada (258)
China (40)
Colorado (41)
Connecticut (24)
Europe (15671)
Florida (70)
Georgia (20)
Illinois (29)
Indiana (53)
Maryland (124)
Massachusetts (296)
Minnesota (26)
New Jersey (259)
New York (113)
North Carolina (135)
Northern California (244)
Ohio (26)
Pennsylvania (102)
South America (187)
Southern California (167)
Texas (68)
Washington State (27)
103,475 Results for "novo holdings".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Editorial
Why It’s OK to Talk About Catalent’s Pending Buyout by ‘Novo’
The group of like-named companies that include Novo Holdings and Novo Nordisk—the two tied to a multibillion-dollar buyout of Catalent currently under FTC review—ultimately send proceeds to the Novo Nordisk Foundation, one of the world’s largest charitable foundations.
October 24, 2024
·
6 min read
·
Jef Akst
GLP-1
FDA Says All Doses of Novo’s Ozempic, Wegovy Now Available
Wednesday’s update to the regulator’s drug shortage database is good news for Novo Nordisk, which has struggled to keep up with demand for the blockbuster GLP-1 drugs.
October 31, 2024
·
2 min read
·
Tristan Manalac
Editorial
Pressure Mounts on Novo’s $16.5B Catalent Buy Amid FTC Review
Senator Elizabeth Warren told the Federal Trade Commission that the acquisition of contract manufacturer Catalent could increase Novo’s dominance over the hot GLP-1 market, reducing competition and increasing prices.
October 11, 2024
·
3 min read
·
Greg Slabodkin
GLP-1
Novo’s Wegovy Comparable to Madrigal’s Rezdiffra in Phase III MASH Trial: Analysts
In part 1 of the pivotal ESSENCE trial, Novo Nordisk’s weight loss drug Wegovy demonstrated “statistically significant and superior improvement” in liver fibrosis in patients with metabolic dysfunction–associated steatohepatitis.
November 1, 2024
·
3 min read
·
Heather McKenzie
Mergers & acquisitions
Unions, Public Interest Groups Call on FTC to Challenge Novo Holdings-Catalent Acquisition
Pressure has been mounting for the Federal Trade Commission to take action, with Senator Elizabeth Warren last week urging FTC Chair Lina Khan to block the merger if it violates antitrust laws.
October 18, 2024
·
2 min read
·
Tristan Manalac
GLP-1
Novo’s Semaglutide Linked to Reduced Alzheimer’s Risk in Real-World Study
Researchers have linked Novo Nordisk’s semaglutide to a 40% to 70% reduction in the risk of Alzheimer’s disease diagnosis in a study of medical records from 1 million patients.
October 24, 2024
·
2 min read
·
Annalee Armstrong
Deals
Catalent Stockholders Approve Transaction with Novo Holdings
Catalent, Inc. announced that, at its Special Meeting of Stockholders held earlier today, its stockholders voted to approve the pending transaction under which Novo Holdings A/S will acquire all outstanding shares of Catalent for $63.50 per share in cash.
May 29, 2024
·
7 min read
Drug Development
Novo’s Ozempic Potentially Linked to Lower Opioid Overdose Risk in Diabetics
A retrospective cohort study of more than 33,000 patients with type 2 diabetes showed that Novo Nordisk’s GLP-1 may lower the risk of opioid overdose by 42% to up to 68%.
September 26, 2024
·
2 min read
·
Tristan Manalac
Patents
Novo, Viatris Settle Ozempic Patent Row
Alongside the settlement, Novo and Viatris have asked the U.S. Patent and Trademark Office to terminate its review of the validity of the Danish drugmaker’s semaglutide patents.
October 8, 2024
·
2 min read
·
Tristan Manalac
Policy
Novo’s Ozempic Seen as Shoo-In for Next Round of Medicare Price Negotiations
Novo Nordisk’s blockbuster type 2 diabetes medication is a sure bet for the list of the next 15 drugs whose Medicare prices will be negotiated in 2025 and go into effect in 2027, according to analysts and academics.
September 25, 2024
·
3 min read
·
Greg Slabodkin
1 of 10,348
Next
